Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.09 USD
Change Today +0.003 / 3.66%
Volume 3.7K
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

boston therapeutics inc (BTHE) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/18/14 - $0.80
52 Week Low
07/7/15 - $0.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

boston therapeutics inc (BTHE) Related Businessweek News

No Related Businessweek News Found

boston therapeutics inc (BTHE) Details

Boston Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases. It produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy post-meal blood glucose levels. The company’s lead product candidates include BTI-320, a non-systemic, carbohydrate based compound, which has completed a Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients; and IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes. It is also developing OxyFex for use as an oxygen delivery agent for ischemia and trauma, as well as for blood loss during surgery in veterinary medicine applications. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Manchester, New Hampshire.

7 Employees
Last Reported Date: 04/28/15
Founded in 2009

boston therapeutics inc (BTHE) Top Compensated Officers

Chairman, Chief Executive Officer, Founder, C...
Total Annual Compensation: $100.0K
Compensation as of Fiscal Year 2014.

boston therapeutics inc (BTHE) Key Developments

Boston Therapeutics, Inc. Announces Executive Changes

On September 1, 2015, the Chief Financial Officer of Boston Therapeutics, Inc., Tony Squeglia, submitted his letter of resignation as an officer and employee of the company for health reasons. Until a successor is appointed, the company's Chief Executive Officer, David Platt, will serve as Chief Financial Officer.

Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Boston Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $38,851 compared to revenue of $21,391 a year ago. The increase is primarily related to larger shipments to Advance Pharmaceutical as compared to the three months ended June 30, 2014. Net loss was $686,238 or $0.02 per basic and diluted share, against $1,211,095 or $0.03 per basic and diluted share a year ago. Operating loss was $511,237 compared to $1,206,107 a year ago. For the six months, the company reported revenue of $90,180 compared to revenue of $65,218 a year ago. Net loss was $1,362,525 or $0.04 per basic and diluted share, against $2,778,239 or $0.07 per basic and diluted share a year ago. Operating loss was $1,246,110 compared to $2,764,237 a year ago.

Boston Therapeutics, Inc. and Benchworks SD LLC Announce Termination of Marketing Agreement

On July 10, 2015, Boston Therapeutics, Inc. was notified by Benchworks SD LLC that Benchworks was terminating the Marketing Agreement dated as of May 14, 2014 between the company and Benchworks effective July 9, 2015. The Agreement expired by its terms on May 14, 2015 but the parties had continued to operate under the terms of the Agreement on an at will basis following the expiration. Under the terms of the Agreement, the company had granted Benchworks the exclusive right to promote, market, sell and distribute SUGARDOWN, the company's dietary product for diabetes, pre-diabetes and blood sugar management, in North America for an initial term of one year, subject to extension in accordance with the terms of the Agreement. Benchworks was responsible for and bore the expense for marketing an commercializing SUGARDOWN, including the creation and payment for marketing, creative and promotional materials. The Agreement defined certain minimum net sales levels that Benchworks must achieve to maintain exclusivity and provided for splits of net revenues from the sale of SUGARDOWN in the Territory between the company and Benchworks.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTHE:US $0.09 USD +0.003

BTHE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTHE.
View Industry Companies

Industry Analysis


Industry Average

Valuation BTHE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at